Notably, our genomic alteration in metastatic tumor data shows that KEAP1 mutations are enriched in BRAF Class 2 NSCLCs, suggesting that cooperation between Class 2 BRAF mutations and KEAP1 loss-of-function mutations may promote cancer progression. Here, BRAF is linked to metastatic neoplasm.